1. Introduction

Artificial placenta accountability governance refers to the legal, ethical, scientific and institutional framework governing the development, testing and use of artificial placenta systems, including responsibility for safety, clinical decisions, informed consent, fetal interests, medical negligence, regulatory oversight and long-term outcomes.

An artificial placenta is an experimental technology designed to support extremely premature fetuses in a fluid-filled environment that imitates certain functions of the womb. It may use an artificial amniotic environment and an extracorporeal circulation system to support developing organs. It is distinct from a conventional neonatal incubator, which supports a baby after delivery using established neonatal-care methods.

The technology raises difficult questions:

Who is legally responsible if the artificial placenta causes injury?

How should decisions be made when the pregnant person's interests and the fetus's interests differ?

Who is accountable for experimental treatment decisions?

What standard of informed consent applies when long-term risks remain uncertain?

How should manufacturers, hospitals, researchers and regulators divide responsibility?

Who monitors the child's health after experimental treatment?

Important legal qualification: There is not yet a settled, comprehensive body of case law specifically governing artificial placenta systems. The doctrine must therefore be developed by applying established principles of medical negligence, research ethics, reproductive autonomy, product liability, constitutional law and administrative accountability.

2. Meaning and scope of accountability governance

Accountability governance means that every institution or individual exercising decision-making power over an artificial placenta system must be identifiable, subject to oversight, required to explain decisions, and capable of being held legally responsible for failures.

Its principal elements are:

Clinical accountability: Responsibility for treatment decisions, monitoring, emergency intervention and compliance with professional standards.

Research accountability: Responsibility for ethical approval, valid consent, scientific integrity and reporting adverse events.

Product accountability: Responsibility for defective devices, inadequate warnings, manufacturing failures and software or equipment malfunction.

Regulatory accountability: Responsibility of public authorities for lawful approval, supervision, investigation and enforcement.

Parental and fetal-interest governance: Protection of the pregnant person's autonomy and appropriate consideration of fetal and future-child welfare.

Post-treatment accountability: Long-term follow-up, developmental assessment, privacy protection and transparent reporting of outcomes.

These elements should operate together rather than as separate, disconnected compliance procedures.

3. Principal case laws and their relevance

The following decisions do not directly adjudicate artificial placenta technology. They provide the legal principles most relevant to future disputes involving experimental gestational support, medical devices and neonatal treatment.

Case 1: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient consented to a diagnostic procedure but underwent additional surgery involving the removal of reproductive organs while under anaesthesia. The dispute concerned the scope and validity of her consent.

Legal principle: The Supreme Court emphasized the importance of valid consent and held that consent for one procedure does not ordinarily authorize a substantially different procedure. An exception may apply where an additional intervention is necessary to save life or preserve health and delaying it would be unreasonable.

Indian Kanoon

+1

Application to artificial placenta governance:

Suppose a hospital proposes transferring an extremely premature newborn to an experimental artificial placenta system. The parents consent to one protocol, but clinicians decide to undertake a materially different intervention with additional risks.

The principles in Samira Kohli support requiring:

Specific, voluntary and adequately informed consent.

Disclosure of material risks, alternatives and foreseeable consequences.

Clear limits on the interventions authorized by the consent.

Separate authorization for materially different research procedures, subject to genuine emergencies and applicable law.

A parent’s signature should not be treated as blanket permission for every experimental procedure. Equally, parental consent cannot eliminate the independent professional duty to protect the patient.

Case 2: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Facts: The case concerned alleged medical negligence associated with inadequate emergency oxygen arrangements and a patient's death.

Legal principle: The Court explained the distinction between civil and criminal medical negligence. Criminal liability requires a substantially higher degree of negligence than an ordinary error of judgment; professional conduct must be assessed against the applicable standard of reasonable medical competence.

Law Today Live

+1

Application to artificial placenta governance:

Imagine that an artificial placenta circuit fails because hospital staff did not maintain backup equipment or follow required monitoring protocols.

Potential legal questions would include:

Did the clinician owe a duty of care?

Was the applicable professional standard breached?

Did that breach cause the injury?

Was the failure attributable to an individual, hospital system or manufacturer?

Does the evidence support civil liability, disciplinary action or, under the relevant jurisdiction's demanding threshold, criminal negligence?

The fact that a technology is experimental does not automatically excuse avoidable negligence. However, an adverse outcome alone does not prove negligence, particularly where clinicians acted reasonably in circumstances of genuine scientific uncertainty.

Case 3: Cruzan v. Director, Missouri Department of Health (1990)

United States Supreme Court · 497 U.S. 261

Facts: The case concerned the withdrawal of life-sustaining treatment from an incompetent patient and the evidentiary requirements for determining the patient's wishes.

Legal principle: The Court recognized a constitutionally protected liberty interest in refusing unwanted medical treatment, while permitting the state to impose safeguards concerning decisions made on behalf of an incompetent person.

Justia U.S. Supreme Court Center

+1

Application to artificial placenta governance:

An artificial placenta may sustain biological functions through continuous technological intervention. Questions could arise when the system becomes ineffective, causes serious complications, or is no longer consistent with the patient's best interests.

The case offers an analogy for governance of treatment limitation and withdrawal, but it does not establish a specific right to withdraw an artificial placenta system.

A responsible decision-making framework should consider:

The patient's clinical prognosis and suffering.

Whether continued treatment offers a meaningful prospect of benefit.

Applicable rules on surrogate decision-making and best interests.

Consultation with the treating team and, where appropriate, an independent ethics committee.

Lawful dispute-resolution procedures when the family and clinicians disagree.

The central lesson is that life-sustaining technology requires an accountable decision-making process, not merely a technical decision about whether a machine can continue operating.

Case 4: In re Quinlan (1976)

Supreme Court of New Jersey · 70 N.J. 10

Facts: Karen Ann Quinlan suffered severe brain injury and remained dependent on artificial ventilation. Her family sought judicial authority to discontinue the ventilator.

Legal principle: The Court considered privacy, medical judgment, the state's interest in preserving life and the institutional safeguards appropriate to withdrawal of life-sustaining treatment.

Justia Law

Application to artificial placenta governance:

The case illustrates the need to allocate decision-making authority among clinicians, families and institutions when advanced technology sustains life in circumstances of grave uncertainty.

For artificial placenta systems, hospitals should establish advance procedures for:

Clinical deterioration and emergency decisions.

Disagreements about continued treatment.

Independent review of disputed treatment plans.

Documentation of prognostic uncertainty.

Escalation to an ethics committee or court when legally necessary.

The case does not determine the legal status of a fetus supported by an artificial placenta. That status must be determined under the relevant jurisdiction's legislation and case law.

Case 5: St George's Healthcare NHS Trust v. S (1998)

England and Wales Court of Appeal · [1998] 3 All ER 673

Facts: The dispute involved a pregnant woman who refused a caesarean section despite medical concerns about the fetus.

Legal principle: The Court of Appeal reaffirmed the importance of a competent adult patient's bodily autonomy and rejected the use of medical intervention against her competent refusal merely to protect the fetus. The artificial-womb literature also discusses this line of authority when examining reproductive autonomy.

PubMed Central (PMC)

Application to artificial placenta governance:

Artificial placenta technology must not be used to create coercive medical expectations during pregnancy. In particular, its potential availability should not automatically authorize:

Surgery against a competent pregnant person's wishes.

Compulsory transfer of a fetus to an artificial gestational system.

Giving a genetic parent an automatic veto over the pregnant person's medical decisions.

Treating technological feasibility as a substitute for lawful consent.

This principle is especially important if future technology permits earlier transfer from the uterus to an artificial gestational environment.

Case 6: Bolam v. Friern Hospital Management Committee (1957)

Queen's Bench Division · [1957] 1 WLR 582

Facts: The case concerned alleged negligence in psychiatric treatment and the standard used to evaluate professional medical conduct.

Legal principle: Traditionally, Bolam is associated with the proposition that a clinician's conduct may be assessed against a responsible body of professional medical opinion. Its application and limits vary by jurisdiction, and professional opinion is not necessarily conclusive in every case.

Application to artificial placenta governance:

Because artificial placenta technology is experimental, courts may need evidence about:

The state of scientific knowledge when treatment was provided.

The quality of the clinical protocol.

Whether the risks were reasonably assessed and disclosed.

Whether independent oversight and monitoring were appropriate.

Whether the clinician followed defensible practices for the stage of research.

A hospital should not be able to defend an unsafe experimental protocol merely by claiming that a group of practitioners accepted it. Scientific validity, regulatory compliance and the actual circumstances of the injury remain relevant.

Case 7: Suchita Srivastava v. Chandigarh Administration (2009)

Supreme Court of India · (2009) 9 SCC 1

Facts: The case concerned the reproductive autonomy of a woman with an intellectual disability and whether her pregnancy could be terminated without her consent.

Legal principle: The Court recognized reproductive choice as part of personal liberty under Article 21 of the Constitution, emphasizing dignity, privacy and bodily integrity.

Supreme Court

+1

Application to artificial placenta governance:

This judgment is important if artificial placenta technology is proposed as an alternative to continuing a pregnancy. It supports the principle that reproductive decisions cannot be reduced to a medical or technological calculation.

A regulatory framework should distinguish between:

Treatment of an extremely premature infant after delivery.

Intervention requiring surgery on a pregnant person.

Future applications involving partial or complete artificial gestation.

Decisions about pregnancy termination, which remain governed by applicable law.

The availability of artificial gestation must not itself extinguish reproductive autonomy or authorize compulsory medical intervention.

Case 8: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Legal principle: The nine-judge Bench recognized privacy as a fundamental right, including dimensions of dignity, personal autonomy and intimate decision-making.

PRIVACY

+1

Application to artificial placenta governance:

Artificial placenta treatment may generate extensive information about fetal development, genetic characteristics, physiological responses and future health risks.

Hospitals and manufacturers should therefore establish rules governing:

Collection and storage of physiological and genetic data.

Access to medical records by parents, clinicians and researchers.

Secondary use of data for commercial research.

Disclosure of identifiable information.

Security of connected monitoring systems.

Appropriate protection of the child's privacy as they grow older.

The constitutional privacy framework is particularly relevant in India, although the precise duties applicable to particular datasets and institutions depend on the governing legislation.

4. Statutory and regulatory framework in India

Artificial placenta governance in India would require analysis of several overlapping legal frameworks. The exact applicability of each enactment depends on the technology's design, intended use, research protocol and clinical setting.

The Indian Council of Medical Research's ethical framework emphasizes autonomy, non-maleficence, justice, privacy, risk minimization and valid consent. These principles are directly relevant when designing research involving an artificial placenta, though the precise legal force of particular guidelines depends on the applicable framework.

Government of India

+2

A further distinction is essential: the Assisted Reproductive Technology (Regulation) Act, 2021, does not automatically govern every artificial placenta intervention. Its provisions concerning assisted reproductive technology and embryo research must be assessed against the actual procedure being performed.

IndiaCode

+1

5. Allocation of legal responsibility

Accountability is most effective when responsibilities are assigned before a device enters clinical use.

Treating clinicians

Responsible for patient assessment, treatment decisions, monitoring, emergency response, valid consent and clinical documentation.

Hospitals and research institutions

Responsible for staffing, training, emergency backup, equipment maintenance, ethics approval, incident reporting and institutional oversight.

Manufacturers and technology suppliers

Potentially responsible for design defects, manufacturing defects, inadequate warnings, foreseeable software failures and failures to communicate safety information.

Regulatory and ethics authorities

Responsible for exercising their respective statutory or institutional powers lawfully, reviewing evidence and responding appropriately to safety concerns.

These responsibilities can overlap. For example, if a device's oxygenation control fails because of both a design defect and inadequate hospital maintenance, more than one party may bear responsibility, subject to proof of causation and the relevant legal rules.

6. Core governance problems

A. Informed consent and experimental uncertainty

Consent must explain that an artificial placenta is experimental and that the likelihood of success, developmental outcomes and long-term risks may be uncertain.

Researchers should distinguish between treatment intended to benefit the patient and procedures undertaken primarily to generate scientific knowledge.

Where treatment concerns a newborn who cannot consent, parental or other legally authorized permission must be obtained under the applicable law. Independent ethical oversight and safeguards for the child's interests are also essential.

B. Clinical negligence and causation

An adverse outcome may arise from an underlying condition, an unavoidable complication, a device defect, a clinician's error or a combination of factors.

A defensible investigation should preserve:

Device logs and monitoring records.

Clinical notes and treatment decisions.

Equipment inspection and maintenance records.

Consent documents and research protocols.

Incident reports and relevant communications.

Expert evidence about causation and the standard of care.

This prevents institutions from treating every complication as unavoidable or, conversely, assuming that every unsuccessful treatment proves negligence.

C. Regulatory transparency

A responsible regulator should require clear standards for device testing, clinical-trial authorization, reporting of serious adverse events, suspension of unsafe studies and independent review.

Researchers should disclose conflicts of interest and report unfavourable outcomes, not merely successful cases.

The regulatory framework must also distinguish the use of an artificial placenta to support an extremely premature newborn from technology intended to replace the entire process of gestation. These are scientifically and ethically distinct applications.

Journal of Perinatology

+1

D. Long-term responsibility

Accountability should not end when the device is disconnected or the patient leaves the hospital.

Depending on the research protocol and applicable law, follow-up may be needed to assess neurological development, organ function, growth, psychological outcomes and other possible delayed effects.

The framework should identify who funds follow-up, who maintains records, how families receive new safety information, and how research-related injuries are handled.

7. Hypothetical case study

Suppose a hospital enrolls an extremely premature newborn in an approved artificial placenta study. The parents receive incomplete information about the possibility of circuit failure. During treatment, a monitoring fault goes undetected, resulting in serious injury.

The legal analysis would proceed in stages:

Consent: Was the study adequately explained, and was valid permission obtained?

Clinical conduct: Did the staff follow the applicable monitoring and emergency protocols?

Device safety: Was the malfunction caused by a defect, inadequate instructions or improper maintenance?

Institutional oversight: Were staffing, training and emergency backup adequate?

Causation and loss: What evidence connects the breach to the injury?

Remedies: Are compensation, consumer proceedings, professional discipline, regulatory action or criminal proceedings available under the applicable law?

The case should not automatically be classified as criminal negligence. Each form of liability has its own legal requirements and evidentiary threshold.

8. Proposed accountability model

A robust artificial placenta governance system should adopt the following safeguards.

Preclinical validation: Require evidence of safety and physiological performance before human testing.

Independent ethics review: Examine participant selection, scientific justification, consent and risk-benefit assessment.

Strict eligibility criteria: Enroll only participants who meet a defensible protocol, without exploiting vulnerable families.

Continuous monitoring: Require clear alarm thresholds, emergency procedures and backup systems.

Mandatory incident reporting: Establish prompt reporting of serious complications and independent investigation of unexpected injuries.

Compensation and insurance: Define responsibility for research-related injury and ensure that families have an accessible route to seek redress.

Independent review of treatment disputes: Create procedures for resolving disagreements about continuation or withdrawal of treatment.

Long-term follow-up: Establish proportionate monitoring and support for children enrolled in experimental studies.

Public accountability: Publish appropriately anonymized findings, including adverse outcomes, study limitations and conflicts of interest.

9. Conclusion

Artificial placenta accountability governance is best understood as a proposed, multidisciplinary framework rather than a settled independent doctrine of law. Its purpose is to ensure that technological innovation does not weaken the established protections of informed consent, professional competence, reproductive autonomy, patient safety and access to remedies.

The most relevant judicial foundations include Samira Kohli for consent, Jacob Mathew for medical negligence, Suchita Srivastava for reproductive autonomy, Puttaswamy for privacy, and Cruzan and In re Quinlan for disputes involving life-sustaining treatment.

The decisive legal question is not simply whether an artificial placenta can sustain life. It is whether every decision surrounding its development and use can be justified, independently reviewed and attributed to a responsible person or institution.

As of October 2026, the technology remains experimental for human clinical use; the legal analysis must therefore distinguish established medical-law principles from proposals for future regulation.

3rd June 2024

+1

This explanation is for academic legal research, not a substitute for jurisdiction-specific legal advice.